Drug Database
CE

cefaclor (Raniclor / Raniclor)

✓ Approved

Ranbaxy Laboratories Limited · Small Molecule · Small Molecule

What is cefaclor?

cefaclor is a small molecule developed by Ranbaxy Laboratories Limited. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesRaniclor, Raniclor
CompanyRanbaxy Laboratories Limited
Drug ClassSmall Molecule
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Ranbaxy Laboratories Limited

Therapeutic Indications

cefaclor is developed for 6 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Infections and infestationsLower respiratory tract infection✓ Approved
Infections and infestationsOtitis media✓ Approved
Infections and infestationsTonsillitis✓ Approved
Infections and infestationsUrinary tract infection✓ Approved
Respiratory, thoracic and mediastinal disordersTonsillar inflammation✓ Approved

+1 more indication available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedJournal of biological engineering2026-08-26

Pharmaceutical polymer-based hydrogels for 3D bioprinted drug delivery and tissue engineering applications.

Bankhede Hemant Kumar HK, Sivaravi Maheswari M, Raiturker Antara Poi AP, Bhende Prajakta Praveen PP et al.

3D bioprinting enables the layer-by-layer fabrication of living tissue constructs and supports patient-specific customization. This technology holds strong promises for regenerative medicine and drug discovery. However, its broader translation remains limited by material variability, safety considerations, cost constraints and regulatory requirements. This study investigates the use of safe, affordable and regulatory-compliant pharmaceutical polymers as biomaterials for 3D bioprinting. It specifically focuses on hydrogels formulated from Starch 1500®, maltodextrin and sodium alginate. The objective is to assess their potential applications in skin tissue engineering and oral drug delivery through semisolid extrusion-based 3D bioprinting techniques. Ionic crosslinking of the hydrogel was confirmed by FTIR analysis. The hydrogel exhibited a viscosity of 1.56 × 106 mPa·s, supporting semisolid extrusion bioprinting and excellent printability under ambient conditions. It enabled the fabrication of multilayer scaffolds with uniform filaments, well-defined square pore geometry and good shape fidelity. Rheological analysis showed shear-thinning behavior under applied stress, 87% thixotropic recovery and predominantly solid-like behavior at rest. Cast films showed a tensile strength of 33.9 MPa with limited extensibility, whereas lyophilized scaffolds exhibited high porosity and an average pore size of 39.2 μm. The 3D-printed scaffolds swollen upto 72% within 24 h and showed the onset of degradation after 2 weeks. Biological evaluation confirmed non-cytotoxicity, with more than 70% cell viability in skin-relevant L929 and HaCaT cells and good hemocompatibility, indicated by 5.0% hemolysis. Confocal microscopy further showed cell growth on the crosslinked hydrogel, supporting their potential for skin tissue engineering. Glimepiride-loaded bioinks were successfully formulated into chewable tablets for drug delivery, which exhibited acceptable physical properties. The tablets demonstrated excellent content uniformity (100.4%), while dissolution results showed sustained-release profiles over a time period of four hours. Our research indicates that pharmaceutical-grade polymer-based hydrogels are promising candidates for skin tissue engineering and drug delivery through 3D bioprinting. The findings of this study underscore the potential of these formulations to advance bioprinting technologies and related applications.

PMID 42642767
Read full article →
PubMedMedicine2026-08-22

Rhabdomyolysis in a 10-month-old child: A case report and literature review.

Shao Hui H, Wang Na N

Early diagnosis and prompt treatment of rhabdomyolysis (RM) in children are crucial to prevent potential complications, such as acute renal failure (ARF). Given that the clinical manifestations of RM in pediatric patients are often atypical, especially in infants, this case report aims to improve the recognition of RM by analyzing a specific clinical case and reviewing relevant literature. A 10-month-old girl was admitted to the hospital with a 3-day history of fever and a 1-day history of cough and rash. The child had no obvious cause of fever and showed no typical symptoms of RM, such as myalgia or myoglobinuria. Physical examination revealed red papules on the skin of the whole body. Laboratory tests showed a significant increase in serum creatine kinase (CK; 119,985 IU/L) and myoglobin (816.7 µg/L). The diagnosis was confirmed as RM based on these laboratory results, despite the absence of the classic clinical triad. The patient received symptomatic and supportive treatments, including atomization with budesonide and ipratropium bromide to relieve cough, oral administration of cefaclor to resist infection, and sodium bicarbonate to alkalize urine and prevent renal damage. In addition, methylprednisolone sodium succinate was used to regulate immunity, along with hepatoprotective agents (reduced glutathione) and myocardial nutrition agents (creatine phosphate sodium). After 13 days of hospitalization, the patient's symptoms (rash, cough, and thrush) disappeared. Laboratory parameters, including CK, CK isoenzyme, liver enzymes, and myoglobin, decreased significantly and returned to normal levels during follow-up. No ARF or recurrence was observed during the 6-month follow-up period. The recognition of RM in children should be improved. Clinicians should be vigilant when encountering atypical symptoms in conjunction with substantially elevated serum CK. Early and accurate diagnosis, along with active fluid resuscitation, can effectively reduce the incidence of ARF and improve prognosis.

PMID 42629679
Read full article →
PubMedThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2026-08-11

Suitability of Oral Formulations Available to Children at the Time of Pediatric Labeling.

Abdel-Rahman Susan M SM, Avant Debbie A DA, Burckart Gilbert J GJ

The pediatric drug development landscape has experienced major shifts, largely in response to legislative and regulatory initiatives. However, associated laws and guidance documents fail to mandate the manufacture of pediatric formulations for commercial marketing post-regulatory approval. This study explores the nature of commercial products available at the time of pediatric labeling. All orally administered drugs for which labeling changes were made from 1998-2024 were evaluated. Characteristics of each drug's commercially marketed formulation(s) at the time of labeling were identified using product labeling (Drugs@FDA), Drugs.com, and DailyMed. During the timeframe reviewed, there were 611 unique labeling changes representing 425 unique drugs available as 567 commercially marketed formulations. Of these drugs, 188 were marketed with pediatric-friendly (PF) formulations. The remainder were available only as solid oral dosage forms. For 329 pediatric labeling changes (53.8%), the only commercially marketed formulation was a solid oral dosage form, in many cases at sizes exceeding reasonable thresholds for the age group. For the remaining 282 labeling changes, a PF formulation was available alone or as a companion to the adult formulation. Among the PF formulations, 62% were suited to direct administration (liquid, orodispersible tablet, chewable/paste, transmucosal) while the remainder required manipulation (i.e. powder/granule, sprinkle/pellet, dispersible tablet). Three-fourths of the PF formulations incorporated flavorings and aromas though 13% failed to report the use of sweeteners. Less than complete access to PF formulations requires attention if we are to maximize the provision of suitable pharmacotherapy for pediatric patients.

PMID 42577924
Read full article →
PubMedThe Journal of small animal practice2026-08-10

Faecal IgA but not salivary IgA is associated with canine atopic dermatitis.

Campbell A A, Nuttall T T, Robinson V V, Soutter F F

To characterise immunoglobulin A (IgA) levels in the faeces and saliva of dogs with canine atopic dermatitis (CAD) and healthy breed matched controls. Dogs with canine atopic dermatitis were recruited based on history, clinical examination and diagnostic testing where appropriate. Control dogs were over 4 years of age with no history of skin disease. Saliva samples were obtained using chewable synthetic swabs with saliva extracted by centrifugation. Faecal samples were collected from the ground before homogenisation in phosphate buffered saline and centrifugation to extract faecal supernatant. Total immunoglobulin A in saliva and faecal supernatants was measured using a commercial dog immunoglobulin A ELISA kit. Immunoglobulin A concentration was interpolated from a six-point standard curve. Mann-Whitney tests were performed to compare immunoglobulin A concentrations between cases and controls. Mean ranked faecal immunoglobulin A was significantly lower in dogs with canine atopic dermatitis than controls (difference between medians 0.803 g/L, 95% CI 0.064 to 1.721). There was no significant difference in mean ranked salivary immunoglobulin A between the groups (difference between medians 0.108 g/L). Faecal immunoglobulin A and salivary immunoglobulin A were not correlated. There were no dogs in either group with both low faecal and low salivary immunoglobulin A suggestive of selective immunoglobulin A deficiency. This study builds on existing evidence that low immunoglobulin A is associated with canine atopic dermatitis. Further work is required to determine the significance of low faecal immunoglobulin A in the development of tolerance or hypersensitivity to food and environmental allergens which may inform strategies for interventions in high-risk breeds.

PMID 42571871
Read full article →
PubMedEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026-08-07

Comparison of oral third- versus first-/ second-generation cephalosporins for acute uncomplicated cystitis: a nationwide retrospective cohort study.

Taniguchi Jumpei J, Aso Shotaro S, Yasunaga Hideo H

Oral cephalosporins are frequently prescribed for uncomplicated cystitis. Although cephalexin and cefaclor (first- and second-generation oral cephalosporins) exhibit favorable pharmacokinetic properties, third-generation agents demonstrate lower and more variable bioavailability, potentially resulting in reduced clinical effectiveness. This study compared oral third-generation cephalosporins with cephalexin and cefaclor in treating uncomplicated cystitis. We conducted a retrospective cohort study using a nationwide claims database in Japan (2006-2022). We included adult women aged ≥ 18 years who newly received oral third-generation (cefdinir, cefpodoxime proxetil, cefditoren pivoxil, or cefcapene pivoxil) or first-/second-generation cephalosporins (cephalexin or cefaclor) for acute uncomplicated cystitis, with a prescription duration of 5-7 days. The primary outcome was a composite of pyelonephritis diagnosis or additional antibiotic use within 7 days. Secondary outcomes included the individual primary outcome components, all-cause hospitalization, and adverse events. We conducted propensity-score overlap weighting to adjust for possible confounders and stratified analyses by age (< 50 or ≥ 50 years). Among 40,003 eligible patients, 90.7% received third-generation cephalosporins. The proportion of the primary outcome was significantly higher in the third-generation group than in the first-/second-generation group (8.4% vs. 6.5%; risk difference, 1.9%; 95% confidence interval, 1.0%-2.7%). Among the secondary outcomes, additional antibiotic treatment was more frequent in the third-generation group, whereas the proportions of pyelonephritis diagnosis and other outcomes were similar between the groups. Subgroup analyses showed consistent results across age strata. Oral third-generation cephalosporins may be associated with more frequent additional antibiotic treatment compared with cephalexin or cefaclor in the management of uncomplicated cystitis.

PMID 42565893
Read full article →
PubMedInternational journal of biological macromolecules2026-08-07

Crosslinked gelatin pastilles prepared via maillard reaction as oral dosage form of ionic liquid pharmaceuticals.

Ng Liu Han LH, Chew Li Ying LY, Yeo Ying Tong YT, Teo Eng Hui EH et al.

Ionic liquid pharmaceuticals (ILP) represent a new class of pharmaceuticals that can circumvent the issues of low aqueous solubility and polymorphism prevalent in pharmaceutical crystals. Due to their highly viscous and hygroscopic nature, ILPs must be formulated into solid dosage forms to ensure their shelf-life stability and dosing accuracy. Gelatin is widely used as carrier matrix for ILPs owed to its high compatibility with various ILPs. Gelatin-based dosage forms, however, exhibit poor storage stability, thereby necessitating reinforcement of the gelatin matrix. The present work investigated the feasibility of employing Maillard reaction (MR)-mediated crosslinking of gelatin with sugars to enhance the storage stability of chewable ILP-loaded gelatin pastilles, while simultaneously conferring taste-masking properties to them. Ionic-liquid pair of poorly-soluble drug ibuprofen (IBU) and 1-butyl-3-methylimidazolium (BMIM) was used as the model ILP. The effects of the degree of gelatin crosslinking, which was modulated by stevia: glucose ratio, on the quality attributes (e.g., dosage uniformity, IBU-BMIM release) and storage stability of the pastilles were evaluated. The results showed MR-mediated crosslinking preserved the liquid-like form of IBU-BMIM in the pastilles, without adverse effect on IBU-BMIM content (≈30 wt%) and its entrapment efficiency (>95 wt%). The pastilles prepared at stevia: glucose = 75:25 (w/w) exhibited 80 wt% IBU-BMIM release after 120 min (intact dosage), high dosage uniformity, and comparable texture/taste profiles as commercial chewable drug tablets. Importantly, the pastilles exhibited good stability after one-month accelerated storage (40°C and 75% relative humidity), as reflected by minimal changes in their quality attributes and high microbiological safety.

PMID 42551677
Read full article →

+2764 more articles available with a free account

Sign up free to view all articles →

Ask about cefaclor